EYEXORA UNIT INKS DEAL WITH SERI TO ADVANCE GLAUCOMA SURGERY

KUALA LUMPUR, Oct 17 (Bernama) -- Y.ora Vision Inc, a new ophthalmic medical device company and spoke company of Eyexora, has announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a minimally invasive glaucoma surgery.

“Our goal is to empower all ophthalmic surgeons with a reliable, minimally invasive, and user-friendly tool that achieves meaningful pressure reduction without the complications or cost of traditional implants.

“We have designed it with the expectation that surgeons will experience a short learning curve, enabling them to more confidently offer this solution to their patients,” said Eyexora Chief Medical Officer, Dr Huan Sheng in a statement.

Developed by SERI researchers and co-inventors Associate Professor Shamira Perera and Professor Michael Belkin, the licensed technology forms the foundation of Y.ora Vision’s proprietary platform (YRA-01).

It is based on a minimally invasive surgical (MIGS) device designed to perform multiple trabeculotomies for mild-to-severe open angle glaucoma (OAG) — a next-generation surgical approach designed to lower intraocular pressure (IOP) safely, effectively, and without the need for permanent implants.

“Our approach was designed for safety, efficiency, and accessibility. By making costly implants unnecessary and simplifying the surgical workflow, Y.ora Vision can help expand access to effective glaucoma care globally,” said Prof Belkin.

YRA-01, a hand-held device that could leverage common equipment in the ophthalmic surgical suite, has the potential to lower IOP in a procedure that can be completed in under 10 minutes and delivers real-time feedback for surgeons.

Glaucoma remains the leading cause of irreversible blindness globally, affecting over 80 million people, with 70 per cent diagnosed with primary open-angle glaucoma. Current surgical treatment options often fall short due to high costs, safety risks, steep learning curves, limited availability and limited efficacy.

-- BERNAMA